Revolution CT to give clinicians a test that gives them outstanding image quality and reduced dose exposure for patients
CHICAGO -- DECEMBER 2, 2013 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced at the Radiological Society of North America's 99th Scientific Assembly and Annual Meeting in Chicago, Illinois that its 510(k)-pending Revolution CT^ has captured a motion free image of the human heart in just one beat.
business unit
tags
Chalfont St Giles, UK and Hsinchu, Taiwan -- 2 December 2013 -- GE Healthcare Life Sciences, (NYSE: GE), and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech's Research Center and manufacturing plant in Hsinchu, Taiwan. The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.
business unit
tags
GE demonstrates the "Power of Partnership" through innovative technologies that improve patient care, comfort and productivity
As the 99th annual meeting of the Radiological Society of North America (#RSNA13) opened today, GE Healthcare, a unit of General Electric Company (NYSE:GE), demonstrated its commitment to delivering innovative healthcare technologies to solve clinicians' most pressing challenges in patient care, comfort and productivity.
business unit
tags
Princeton, NJ -- November 27, 2013 -- GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque™ (iodixanol 320mg I/ml) were less likely to experience discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue® (iopamidol 370 mg I/ml). As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, heat or pain. The data were published online in Acta Radiologica.[i]
business unit
tags
CHALFONT ST. GILES, UK -- 19 November 2013 -- GE Healthcare Life Sciences, (NYSE: GE) and Cellectis Group (Alternext: ALCLS), the global genome engineering specialist, announced today that GE Healthcare has licenced Cellectis to develop, manufacture and sell models derived from stem cells for use in drug discovery and toxicity screening.
business unit
tags
Chalfont St. Giles and Stevenage, UK - 29 October 2013. GE Healthcare Life Sciences, a global provider of tools, technologies and services for life science research and for the manufacturing of biopharmaceuticals, today announced the opening of a Technology Laboratory at Stevenage Bioscience Catalyst, the UK's first open innovation bioscience campus.